Item 5. Other Information
Item 5. Other Information.
On August 11, 2023, the Board of Directors of Rockwell terminated the employment of Marc Hoffman as Chief Medical Officer of the Company, effective immediately. The termination of employment of Dr. Hoffman by the Company without cause entitles Dr. Hoffman to severance in accordance with the Employment Agreement, dated September 24, 2019, by and between the Company and Dr. Hoffman (the “Employment Agreement”). The severance benefits under the Employment Agreement are subject to the execution and non-revocation of a release of claims in favor of the Company. Dr. Hoffman will provide consulting services to the Company for up to one year following his termination to assist with the transition of his responsibilities and other related matters, during which time his unvested equity awards will continue to vest in accordance with their terms.
33
Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.
EXHIBIT INDEX
Exhibit No. Description
4.1 * Common Stock Purchase Warrant, dated July 10, 2023, issued to Armistice Capital Master Fund Ltd.
10.1 * Letter Agreement , dated July 10, 2023, by and between Rockwell Medical, Inc. and Armistice Capital Master Fund Ltd.
10.2 * Asset Purchase Agreement dated July 10, 2023 by and between Rockwell Medical, Inc. and Evoqua Water Technologies LLC.
10.3 * Rockwell Medical, Inc. Amended and Restated 2018 Long Term Incentive Plan.
31.1* Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934
32.1** Certification pursuant to 18 U.S.C. Section 1350 and Rule 13a-14(b) of the Securities Exchange Act of 1934
101.INS* XBRL Instance Document
101.SCH* XBRL Taxonomy Extension Schema
101.CAL* XBRL Taxonomy Extension Calculation Linkbase
101.DEF* XBRL Taxonomy Extension Definition Database
101.LAB* XBRL Taxonomy Extension Label Linkbase
101.PRE* XBRL Taxonomy Extension Presentation Linkbase
104* The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline XBRL (included as Exhibit 101)
* Filed herewith
** Furnished herewith and not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act
34
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ROCKWELL MEDICAL, INC.
(Registrant)
Date: August 14, 2023 /s/ Mark Strobeck
Mark Strobeck, Ph.D.
Chief Executive Officer (Principal Executive Officer and Interim Financial Officer)
35